| 摘要 |
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used for treating ocular hypertension. That is ensured by implanting at least two biodegradable prolonged-release intrachamber implants by means of an applicator into an anterior eye chamber; each implant contains at least one prostamide; each of at least two prolonged-release biodegradable implants mentioned above releases at least one prostamide mentioned above in an amount of 100 nm to 900 nm a day for a service life of the implant; each of at least two prolonged-release biodegradable implants mentioned above contains 5-40% of at least one prostamide, 10-60% of R203S, which is poly(D,L-lactide) possessing a proper viscosity of 0.25-0.35 dl/g, 5-20% of R202H, which is poly(D,L-lactide) possessing a proper viscosity of 0.16-0.24 dl/g, 5-40% of RG752S, which is poly(D,L-lactide-co-glycolide) having a molar ratio of D,L-lactide:glycolude from 73:27 to 77:23 and a proper viscosity of 0.16-0.24 dl/g, and 5-15% of polyethylene glycol (PEG) 3350.EFFECT: method enables increasing the clinical effectiveness for ocular hypertension by injecting the implants into the anterior portion of the vitreous body through a flat portion of the ciliated body while overcoming the transscleral barriers effectively.5 cl, 3 tbl, 2 ex, 6 dwg |
